Fuminori Yoshida remarks

dreams come true

Approval of TREAKISYM

On October 27, 2010, we received notification from the Ministry of Health, Labor and Welfare that TREAKISYM had been approved. This was truly a moment when we were able to "create something out of nothing." At the same time, it was also the first moment when our mission to meet unmet medical needs and our ambition "Symbiosis" was realized. Once again, we would like to express our deepest gratitude to the many doctors, including those on the Scientific Advisory Board (SAB), who provided guidance for the approval of TREAKISYM, and to the many shareholders who invested in us and trusted us, for their support and cooperation in helping us to obtain early approval of TREAKISYM.
I would also like to express my gratitude to our employees who, for the five and a half years since SymBio Pharmaceuticals was founded on March 25, 2005, have worked hard to do their best in their respective positions with a strong desire to provide new drugs to patients as soon as possible, and to their families who have supported them on a daily basis. It is a wonderful achievement that the drug lag between the U.S. and Europe has been reduced to two years, while the U.S. and European countries (excluding Germany) have simultaneously approved the drug with no lag at all, and this has brought great benefits to patients and their families. We are proud of this great achievement.
Looking back over the past five and a half years, we have faced many difficulties in both management and development, and have been pushed to the edge on several occasions. When I think of the joy and smiles on the faces of these patients and their families today, I can say that these hardships were merely a test to help us realize our mission.
Our mission is not limited to the development and provision of TREAKISYM, but is to continue to develop and provide many new drugs for unmet therapeutic areas, and all of us will work together to achieve our next goal. Furthermore, SymBio Pharmaceuticals has high expectations in the pharmaceutical industry for the "birth of Japan's first specialty pharmaceutical company specializing in the three therapeutic areas of oncology, hematology, and autoimmune diseases," and we will continue to work as one to create a pharmaceutical company with a globally competitive business model. We would also like to take this opportunity to share with you that we are working on a grand theme to create a pharmaceutical company with a globally competitive business model.

I would like to ask all concerned parties for their continued guidance and encouragement.

October 27, 2010
Representative Director President and CEO
Fuminori Yoshida